Sandoz Voluntary Recalls Ranitidine Hydrochloride Capsules Due to Elevated Amount of N-Nitrosodimethylamine in the US
Shots:
- Sandoz recalls all quantities and lots of ranitidine hydrochloride capsules (150/300mg) including 30 count- 60 count and 500 count bottles within expiry to the consumer level due to an elevated amount of impurity of NDMA which is classified as a carcinogen in the US. The recall is being conducted with the knowledge of the US FDA
- Sandoz will be notifying its distributors and customers via overnight mail- Sandoz web site- and will arrange for the return of all recalled products. Consumers can contact Sandoz at 1-800-525-8747 option # between 8:30 am – 5:00 pm Monday – Friday EST or www.us.sandoz.com regarding any query about the recall
- Ranitidine Hydrochloride is an oral therapy- indicated for duodenal ulcer- benign gastric ulcer- reflux esophagitis- post-operative peptic ulcer- Zollinger-Ellison Syndrome and other conditions where reduction of gastric secretion and acid output is required
Click here to read full press release/ article | Ref: Sandoz | Image: Finazen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
